Neural correlates of the LSD experience revealed by multimodal neuroimaging

Proceedings of the National Academy of Sciences of the United States of America

Volumn 113, Issue 17, 2016, Pages 4853-4858

  Carhart Harris, Robin L ^a   Muthukumaraswamy, Suresh ^b,c   Roseman, Leor ^a   Kaelen, Mendel ^a   Droog, Wouter ^b   Murphy, Kevin ^b   Tagliazucchi, Enzo ^d,e   Schenberg, Eduardo E ^a,f,g   Nest, Timothy ^h   Orban, Csaba ^a   Leech, Robert ^a   Williams, Luke T ^a   Williams, Tim M ⁱ   Bolstridge, Mark ^a   Sessa, Ben ^a,b   McGonigle, John ^a   Sereno, Martin I ^j   Nichols, David ^k   Hellyer, Peter J ^a   Hobden, Peter ^b   Evans, John ^b   Singh, Krish D ^b   Wise, Richard G ^b   Curran, H Valerie ^j   Feilding, Amanda ^l   Nutt, David J ^a   more..

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

^d UNIVERSITY OF KIEL   (Germany)

^e GOETHE UNIVERSITY   (Germany)

^f FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^g Instituto Plantando Consciencia   (Brazil)

^h MCGILL UNIVERSITY   (Canada)

ⁱ UNIVERSITY OF BRISTOL   (United Kingdom)

^j UNIVERSITY COLLEGE LONDON   (United Kingdom)

^k University of North Carolina   (United States)

^l THE BECKLEY FOUNDATION   (United Kingdom)

more..

Author keywords

Brain; Consciousness; LSD; Psychedelic; Serotonin

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; LYSERGIDE; PSILOCYBINE; OXYGEN; PSYCHEDELIC AGENT; SEROTONIN 2 AGONIST; SEROTONIN 2A RECEPTOR; SPIN LABEL;

ADULT; ALPHA RHYTHM; ARTERIAL SPIN LABELING; BOLD SIGNAL; BRAIN BLOOD FLOW; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; DEFAULT MODE NETWORK; DORSAL ATTENTION NETWORK; EGO; FEMALE; HUMAN; INFERIOR FRONTAL GYRUS; MAGNETOENCEPHALOGRAPHY; MALE; MULTIMODAL IMAGING; MULTIMODAL NEUROIMAGING; NEUROIMAGING; PRIORITY JOURNAL; RETROSPLENIAL CORTEX; SALIENCE NETWORK; SPIN LABELING; STRIATE CORTEX; VISUAL CORTEX; VISUAL HALLUCINATION; BLOOD; BRAIN; BRAIN CIRCULATION; BRAIN MAPPING; CHEMICALLY INDUCED; CONNECTOME; CONSCIOUSNESS; DRUG EFFECTS; HALLUCINATION; NERVE CELL NETWORK; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; SYNAPTIC TRANSMISSION;

BRAIN; BRAIN MAPPING; CEREBROVASCULAR CIRCULATION; CONNECTOME; CONSCIOUSNESS; HALLUCINATIONS; HALLUCINOGENS; HUMANS; LYSERGIC ACID DIETHYLAMIDE; MAGNETIC RESONANCE IMAGING; MAGNETOENCEPHALOGRAPHY; MULTIMODAL IMAGING; NERVE NET; OXYGEN; RECEPTOR, SEROTONIN, 5-HT2A; SEROTONIN 5-HT2 RECEPTOR AGONISTS; SPIN LABELS; SYNAPTIC TRANSMISSION;

EID: 84964792528     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1518377113     Document Type: Article

References (46)

1. Hofmann A (1980) LSD: My Problem Child (McGraw-Hill, New York).
2. Carhart-Harris RL, et al. (2015) LSD enhances suggestibility in healthy volunteers. Psychopharmacology (Berl) 232(4):785-794.
3. Dolder PC, Schmid Y, Haschke M, Rentsch KM, Liechti ME (2015) Pharmacokinetics and Concentration-Effect Relationship of Oral LSD in Humans. Int J Neuropsychopharmacol 19(1):pyv072.
4. Kaelen M, et al. (2015) LSD enhances the emotional response tomusic. Psychopharmacology (Berl) 232(19):3607-3614.
5. Schmid Y, et al. (2015) Acute Effects of Lysergic Acid Diethylamide in Healthy Subjects. Biol Psychiatry 78(8):544-553.
6. Gasser P, et al. (2014) Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. J Nerv Ment Dis 202(7):513-520.
7. Halberstadt AL (2015) Recent advances in the neuropsychopharmacology of serotonergic hallucinogens. Behav Brain Res 277:99-120.
8. Fink M (1969) EEG and human psychopharmacology. Annu Rev Pharmacol 9:241-258.
9. Muthukumaraswamy SD, et al. (2013) Broadband cortical desynchronization underlies the human psychedelic state. J Neurosci 33(38):15171-15183.
10. Kometer M, Pokorny T, Seifritz E, Volleinweider FX (2015) Psilocybin-induced spiritual experiences and insightfulness are associated with synchronization of neuronal oscillations. Psychopharmacology (Berl) 232(19):3663-3676.
11. Riba J, et al. (2002) Topographic pharmaco-EEG mapping of the effects of the South American psychoactive beverage ayahuasca in healthy volunteers. Br J Clin Pharmacol 53(6):613-628.
12. Wood J, Kim Y, Moghaddam B (2012) Disruption of prefrontal cortex large scale neuronal activity by different classes of psychotomimetic drugs. J Neurosci 32(9):3022-3031.
13. Celada P, Puig MV, Díaz-Mataix L, Artigas F (2008) The hallucinogen DOI reduces lowfrequency oscillations in rat prefrontal cortex: Reversal by antipsychotic drugs. Biol Psychiatry 64(5):392-400.
14. Riga MS, Soria G, Tudela R, Artigas F, Celada P (2014) The natural hallucinogen 5-MeODMT, component of Ayahuasca, disrupts cortical function in rats: Reversal by antipsychotic drugs. Int J Neuropsychopharmacol 17(8):1269-1282.
15. Vollenweider FX, et al. (1997) Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis. Neuropsychopharmacology 16(5):357-372.
16. Carhart-Harris RL, et al. (2012) Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proc Natl Acad Sci USA 109(6):2138-2143.
17. Carhart-Harris RL, et al. (2014) The entropic brain: A theory of conscious states informed by neuroimaging research with psychedelic drugs. Front Hum Neurosci 8:20.
18. Petri G, et al. (2014) Homological scaffolds of brain functional networks. J R Soc Interface 11(101):20140873.
19. Tagliazucchi E, Carhart-Harris R, Leech R, Nutt D, Chialvo DR (2014) Enhanced repertoire of brain dynamical states during the psychedelic experience. Hum Brain Mapp 35:5442-5456.
20. Palhano-Fontes F, et al. (2015) The psychedelic state induced by ayahuasca modulates the activity and connectivity of the default mode network. PLoS One 10(2):e0118143.
21. Monroe RR, Heath RG (1961) Effects of lysergic acid and various derivatives on depth and cortical electrograms. J Neuropsychiatry 3:75-82.
22. Schwarz BE, Sem-Jacobsen CW, Petersen MC (1956) Effects of mescaline, LSD-25, and adrenochrome on depth electrograms in man. AMA Arch Neurol Psychiatry 75(6):579-587.
23. Serafetinides EA (1965) The EEG effects of LSD-25 in epileptic patients before and after temporal lobectomy. Psychopharmacology (Berl) 7(6):453-460.
24. Mégevand P, et al. (2014) Seeing scenes: Topographic visual hallucinations evoked by direct electrical stimulation of the parahippocampal place area. J Neurosci 34(16):5399-5405.
25. Vignal JP, Maillard L, McGonigal A, Chauvel P (2007) The dreamy state: Hallucinations of autobiographic memory evoked by temporal lobe stimulations and seizures. Brain 130(Pt 1):88-99.
26. Studerus E, Gamma A, Vollenweider FX (2010) Psychometric evaluation of the altered states of consciousness rating scale (OAV). PLoS One 5(8):e12412.
27. Gorgolewski KJ, et al. (2015) NeuroVault.org: A web-based repository for collecting and sharing unthresholded statistical maps of the human brain. Front Neuroinform 9:8.
28. Carhart-Harris RL, et al. (2015) The effects of acutely administered 3,4-methylenedioxymethamphetamine on spontaneous brain function in healthy volunteers measured with arterial spin labeling and blood oxygen level-dependent resting state functional connectivity. Biol Psychiatry 78(8):554-562.
29. Kometer M, Schmidt A, Jäncke L, Vollenweider FX (2013) Activation of serotonin 2A receptors underlies the psilocybin-induced effects on ? oscillations, N170 visualevoked potentials, and visual hallucinations. J Neurosci 33(25):10544-10551.
30. Butler TC, et al. (2012) Evolutionary constraints on visual cortex architecture from the dynamics of hallucinations. Proc Natl Acad Sci USA 109(2):606-609.
31. de Araujo DB, et al. (2012) Seeing with the eyes shut: Neural basis of enhanced imagery following Ayahuasca ingestion. Hum Brain Mapp 33(11):2550-2560.
32. Tolias AS, et al. (2005) Mapping cortical activity elicited with electrical microstimulation using FMRI in the macaque. Neuron 48(6):901-911.
33. Cavonius CR, Estévez-Uscanga O (1974) Local suppression of alpha activity by pattern in half the visual field. Nature 251(5474):412-414.
34. Jensen O, Mazaheri A (2010) Shaping functional architecture by oscillatory alpha activity: Gating by inhibition. Front Hum Neurosci 4:186.
35. Shirahashi K (1960) Electroencephalographic study of mental disturbances experimentally induced by LSD25. Psychiatry Clin Neurosci 14(2):140-155.
36. Horikawa T, Tamaki M, Miyawaki Y, Kamitani Y (2013) Neural decoding of visual imagery during sleep. Science 340(6132):639-642.
37. Lebedev AV, et al. (2015) Finding the self by losing the self: Neural correlates of egodissolution under psilocybin. Hum Brain Mapp 36(8):3137-3153.
38. Kapur S (2003) Psychosis as a state of aberrant salience: A framework linking biology, phenomenology, and pharmacology in schizophrenia. Am J Psychiatry 160(1):13-23.
39. Friston KJ, Frith CD (1995) Schizophrenia: A disconnection syndrome? Clin Neurosci 3(2):89-97.
40. Seidman LJ, et al. (2014) Medial temporal lobe default mode functioning and hippocampal structure as vulnerability indicators for schizophrenia: A MRI study of nonpsychotic adolescent first-degree relatives. Schizophr Res 159(2-3):426-434.
41. Lui S, et al. (2015) Resting-state brain function in schizophrenia and psychotic bipolar probands and their first-degree relatives. Psychol Med 45(1):97-108.
42. Roseman L, Leech R, Feilding A, Nutt DJ, Carhart-Harris RL (2014) The effects of psilocybin and MDMA on between-network resting state functional connectivity in healthy volunteers. Front Hum Neurosci 8:204.
43. Dyer DC, Gant DW (1973) Vasoconstriction produced by hallucinogens on isolated human and sheep umbilical vasculature. J Pharmacol Exp Ther 184(2):366-375.
44. Grob CS, et al. (2011) Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry 68(1):71-78.
45. Bogenschutz MP, et al. (2015) Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study. J Psychopharmacol 29(3):289-299.
46. Johnson MW, Garcia-Romeu A, Cosimano MP, Griffiths RR (2014) Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. J Psychopharmacol 28(11):983-992.